Addendum
Ribociclib (breast cancer, combination with an aromatase inhibitor) - Addendum to commission A20-21
Report documents
-
Addendum
Ribociclib (breast cancer, combination with an aromatase inhibitor) - Addendum to commission A20-21
Dossier assessment
Indication:
| Initial endocrine therapy in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer |
Result of dossier assessment:
| Conclusion of dossier assessment A20-21 unchanged: added benefit still not proven. |
Additional information
Federal Joint Committee (G-BA)
20.08.2020 A G-BA decision was published.
Project details
- Project no.
- A20-57
- Commission
- Commission awarded on 06.07.2020 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Ribociclib (breast cancer; combination with aromatase inhibitors) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed